Protective Conditioning for Acute Graft-versus-Host Disease

Robert Lowsky(Stanford University), Tsuyoshi Takahashi(Stanford University), Yin Ping Liu(Stanford University), Sussan Dejbakhsh‐Jones(Stanford University), F. Carl Grumet(Stanford University), Judith A. Shizuru(Stanford University), Ginna G. Laport(Stanford University), Keith Stockerl‐Goldstein(Stanford University), Laura Johnston(Stanford University), Richard T. Hoppe(Stanford Medicine), D. Blöch(Stanford Health Care), Karl G. Blume(Stanford University), Robert S. Negrin(Stanford University), Samuel Strober(Stanford University)
New England Journal of Medicine
September 28, 2005
Cited by 327Open Access
Full Text

Abstract

BACKGROUND: Conditioning with total lymphoid irradiation plus antithymocyte serum protects mice against acute graft-versus-host disease (GVHD) after hematopoietic-cell transplantation. We tested this strategy in humans. METHODS: Thirty-seven patients with lymphoid malignant diseases or acute leukemia underwent an experimental conditioning regimen with 10 doses of total lymphoid irradiation (80 cGy each) plus antithymocyte globulin, followed by an infusion of HLA-matched peripheral-blood mononuclear cells from related or unrelated donors who received granulocyte colony-stimulating factor. RESULTS: Of the 37 transplant recipients, only 2 had acute GVHD after hematopoietic-cell transplantation. Potent antitumor effects in patients with lymphoid malignant diseases were shown by the change from partial to complete remission. In the transplant recipients who underwent conditioning with total lymphoid irradiation and antithymocyte globulin, the fraction of donor CD4+ T cells that produced interleukin-4 after in vitro stimulation increased by a factor of five, and the proliferative response to alloantigens in vitro was reduced, as compared with normal control subjects and control subjects who underwent conditioning with a single dose of total-body irradiation (200 cGy). CONCLUSIONS: A regimen of total lymphoid irradiation plus antithymocyte globulin decreases the incidence of acute GVHD and allows graft antitumor activity in patients with lymphoid malignant diseases or acute leukemia treated with hematopoietic-cell transplantation.


Related Papers

No related papers found

Powered by citation graph analysis